Attention-deficit/hyperactivity disorder in adults: Evidence-based recommendations for management

Postgraduate Medicine

Volumn 120, Issue 3, 2008, Pages 27-38

  Rostain, Anthony L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADHD; Amphetamine salts; Atomoxetine; Attention deficit hyperactivity disorder; Cognitive behavioral therapy; Methylphenidate

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; IMIPRAMINE; METHYLPHENIDATE; OROS; PLACEBO; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ADJUVANT THERAPY; ADULT; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISORIENTATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; IRRITABILITY; LOW DRUG DOSE; MOOD DISORDER; NAUSEA; NERVOUSNESS; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; XEROSTOMIA; REVIEW;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITIVE THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 56149123282     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.09.1905     Document Type: Article

References (83)

1. Wilens TE, Biederman J, Spencer TJ. Attention deficit hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113-131. (Pubitemid 34177874)
2. Kessler RC, Adler LA, Ames M, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565-572. (Pubitemid 40847440)
3. Murphy K, Barkley R. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord. 1996;1:147-161. (Pubitemid 126739020)
4. Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Am Coll Health. 1998;46(4):185-188. (Pubitemid 28110429)
5. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. (Pubitemid 44464584)
7. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. (Pubitemid 43126140)
8. Davidson MA. ADHD in adults: a review of the literature. J Atten Disord. 2008;11(6):628-641.
9. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/ hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000; 48(1):9-20. (Pubitemid 30407145)
10. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(12):1792-1798. (Pubitemid 23356570)
11. Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8(5):655-672. (Pubitemid 34928352)
12. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: Results from the WHO World Mental Health Survey Initiative. Occup Environ Med. In press.
13. Sankaranarayanan J, Puumala SE, Kratochvil CJ. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Curr Med Res Opin. 2006;22(8):1475-1491.
14. Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164(11):1221-1226. (Pubitemid 39030359)
15. Van Brunt DL, Johnston JA, Ye W, Pohl GM, O'Hara NN. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm. 2006;12(3):230-238. (Pubitemid 47400612)
16. Spencer T, Biederman J, Wilens T. Stimulant treatment of adult attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):361-372. (Pubitemid 38452772)
17. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention-deficit/hyperactivity disorder: Findings from multiplex families. Am J Psychiatry. 2005;162(9):1621-1627. (Pubitemid 41318230)
18. Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163(10):1720-1729. (Pubitemid 44522480)
19. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161(11):1948-1956. (Pubitemid 39441393)
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
21. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2006. http://www.who.int/classifications/apps/icd/icd10online/. Accessed November 30, 2006.
22. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British association for psychopharmacology. J Psychopharmacol. 2007;21(1):10-41. (Pubitemid 46012081)
23. Faraone SV, Biederman J, Doyle A, et al. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;60(10):1081-1087. (Pubitemid 44754858)
24. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2006.
25. Greenhill LL, Pliszka S, Dulcan MK; American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolcsc Psychiatry. 2002;41(suppl 2):26S-49S.
26. Wender PH, Reimherr FW, Wood DR. Attention-deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981;38(4):449-456. (Pubitemid 11156030)
27. Brown T. Brown Attention Deficit Disorder Scales: Manual. San Antonio, TX: Pearson Education, Inc; 1996.
28. Conners CK, Erhardt D, Sparrow E, Conners MA. CAARS Adult ADHD Rating Scales. New York, NY: Multi Health Systems; 1998.
29. Adler LA, Kessler RC, Spencer T. Adult ADHD Self-Report Scale-v 1.1 (ASRS-v1.1) symptom checklist. NYU Langone Medical Center website. Updated 2004. http://www.med.nyu.edu/psych/assets/adhdscreen18.pdf. Accessed November 27, 2006.
30. Spencer T, Adler L. Diagnostic approaches to adult attention-deficit/ hyperactivity disorder. Prim Psychiatry. 2004;11:49-53. (Pubitemid 39006708)
31. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders. Addiction. 2005;100(12):1868-1874. (Pubitemid 41775212)
32. Biederman J, Mick E, Spencer T, et al. An open-label trial of OROS® methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006;11(5):390-396. (Pubitemid 43727139)
33. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24-29. (Pubitemid 38134162)
34. Clausen SB, Read SC, Tulloch SJ. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr. 2005;10(12 suppl 20):6-15. (Pubitemid 43010493)
35. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol. 2000;40(4):379-388.
36. Wood DR, Reimherr FW, Wender PH, Johnson EG. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry. 1976;33(12):1453-1460.
37. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984;41(11):1059- 1063. (Pubitemid 14017417)
38. Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985;142(5):547-552. (Pubitemid 15034621)
39. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol. 1985;8(4):343-356.
40. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31(5):416-425. (Pubitemid 20305300)
41. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434-443.
42. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry. 1998;59(6):300-305. (Pubitemid 28353978)
43. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001;13(3):129-134. (Pubitemid 34020146)
44. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2003;48(8):546-554. (Pubitemid 37280044)
45. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34(6):973-982. (Pubitemid 39199967)
46. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456-463. (Pubitemid 40311979)
47. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
48. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68(1):93-101. (Pubitemid 46220130)
49. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(2):268-277. (Pubitemid 46362649)
50. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380-1387. (Pubitemid 46855767)
51. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
52. Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007;7:49. (Pubitemid 350111687)
53. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 1999;33(4):494-502. (Pubitemid 29386870)
54. Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2000;61(6):414-417. (Pubitemid 30452207)
55. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10(4):311-320. (Pubitemid 32103907)
56. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-228. (Pubitemid 32221061)
57. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782. (Pubitemid 32717803)
58. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. SLI381.304 study group. Long-term safely and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 suppl 20):16-25. (Pubitemid 43010494)
59. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639. (Pubitemid 44253518)
60. Weiss M, Hechtman L. The Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006;67(4):611-619. (Pubitemid 43764238)
61. Spencer TJ, Biedeman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry. 1996;35:409-432. (Pubitemid 126418605)
62. Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):373-383. (Pubitemid 38452773)
63. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155(5):693-695. (Pubitemid 28225414)
64. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. (Pubitemid 36126473)
65. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66(3):294-299. (Pubitemid 40476751)
66. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18(2):107-113. (Pubitemid 43879898)
67. Adler LA, Spencer TJ, Williams DW, et al. Long-term open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008 Apr 30. [Epub ahead of print].
68. Faraone SV, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct. 2005;1:16. (Pubitemid 44848779)
69. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-1901. (Pubitemid 35283256)
70. Jain U, Hechtman L, Quinn D, et al. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines: 2006. http://www.caddra.ca/joomla/pdfs/caddraGuidelinesChapter06. pdf. Accessed June 22, 2006.
71. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD: results of an open study of 43 patients. J Atten Disord. 2006;10(2):150-159.
72. Weiss M, Safren SA, Solanto MV, et al. Research forum on psychological treatment of adults with ADHD. J Atten Disord. 2008;11(6):642-651.
73. Ramsay JR. Current status of cognitive-behavioral therapy as a psychosocial treatment for adult attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2007;9(5):427-433. (Pubitemid 47559364)
74. Wilens TE, McDermott SP, Biedeman J, Abrantes A, Hahesy A, Spencer TJ. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cognit Psychother. 1999;13:215-226. (Pubitemid 30010794)
75. Hesslinger B, van Elst LT, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults: a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci. 2002;252(4):177-184. (Pubitemid 36056674)
76. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43(7):831-842. (Pubitemid 40719607)
77. Biederman J, Spencer TJ. Psychopharmacology of adults with attention-deficit/hyperactivity disorder. Prim Psychiatry. 2004;11(7):57-62. (Pubitemid 39006709)
78. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189-202.
79. Olfson M, Marcus SC, Zhang HF, Wan GJ. Stimulant use in adults with attention-deficit/hyperactivity disorder. Poster presented at: the Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Canada.
80. Swanson JM, Lerner MA, Gupta S, Shoulson I, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD. Arch Gen Psychiatry. 2003;60(2):204-211.
81. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275-289. (Pubitemid 41551759)
82. Vetter VL, Elia J, Erickson C, et al. American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423.
83. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999;99(7):979-982. (Pubitemid 29094318)